BCL2L11 and hepatocellular carcinoma: In recent studies, by observing the differential migration response of Hev4 (K8/K18-present HCC cells) and shK8b cells (K8/K18-deficient HCC cells) under PMA (a PKC activator) as well as BIM (a novel PKC inhibitor) treatments and PKC knockout experiments, they found that PKCδ is the mediator of the K8/K18 regulation of FA.